| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11571436 | BRISTOL | NA |
May, 2029
(5 years from now) | |
Onureg is owned by Bristol.
Onureg contains Azacitidine.
Onureg has a total of 1 drug patent out of which 0 drug patents have expired.
Onureg was authorised for market use on 01 September, 2020.
Onureg is available in tablet;oral dosage forms.
The generics of Onureg are possible to be released after 14 May, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 1, 2023 |
| Orphan Drug Exclusivity (ODE) | Sep 1, 2027 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: NA
Dosage: TABLET;ORAL
ONUREG family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846628 | CELGENE CORP | Oral formulations of cytidine analogs and methods of use thereof |
Jun, 2030
(6 years from now) | |
Onureg is owned by Celgene Corp.
Onureg contains Azacitidine.
Onureg has a total of 1 drug patent out of which 0 drug patents have expired.
Onureg was authorised for market use on 01 September, 2020.
Onureg is available in tablet;oral dosage forms.
Onureg can be used as continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy.
The generics of Onureg are possible to be released after 03 June, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 1, 2023 |
| Orphan Drug Exclusivity (ODE) | Sep 1, 2027 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...
Dosage: TABLET;ORAL
ONUREG family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic